Biotechnology company Moderna protocol files for COVID-19 vaccinations are kept at the Research Centers of America in Hollywood, Florida. (Photo by CHANDAN KHANNA / AFP) (Photo by CHANDAN KHANNA/AFP via Getty Images)

Roche has entered a partnership with Moderna to use the Elecsys Anti-SARS-CoV-2 S antibody test in research trials of the latter’s Covid-19 vaccine, mRNA-1273.

The collaboration will support the quantitative measurement of SARS-CoV-2 antibodies. It will also help to establish a connection between protection induced by the vaccine and levels of anti-receptor binding domain (RBD) antibodies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Moderna’s vaccine is observed to trigger antibody response to the RBD of the SARS-CoV-2 spike protein.

Elecsys Anti-SARS-CoV-2 S is an immunoassay for the quantitative, in vitro determination of antibodies to SARS-CoV-2 in human serum and plasma. The test uses a blood sample to measure the quantity of antibodies that are needed to spike the protein of the virus.

The latest development comes after Roche received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for the antibody test.

Roche Diagnostics CEO Thomas Schinecker said: “Roche values the collaboration with Moderna, which has already included the successful use of our qualitative Elecsys Anti-SARS-CoV-2 test, targeting the nucleocapsid protein, in an earlier part of the studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are pleased to see that our quantitative Elecsys SARS-CoV-2 S test, which targets the spike protein, is now also being used as part of the Moderna vaccine trials, which could ultimately help to end this pandemic.”

Roche’s test can quantitatively measure the levels of anti-RBD SARS-CoV-2 antibodies in vaccine trial subjects and could help to establish a correlation to disease protection.

The test could also be useful in analysing whether an individual needs revaccination or solving other clinically relevant questions.

In October, Roche launched the Elecsys SARS-CoV-2 Antigen Test to offer support to high-volume testing of suspected Covid-19 patients.